What it is
IGF-1 LR3 is Long R3 IGF-1: a modified version of insulin-like growth factor 1, an 83-amino-acid analogue with an extension at one end and a substitution at the third position.
Those modifications sharply reduce how much it is captured by IGF binding proteins — the body's own system for controlling how much free IGF-1 is available at any moment. Evading them is what makes this version long-acting and, in a dish, far more potent than the natural hormone.
What it was actually made for
Cell culture.
In a dish, binding proteins mop up ordinary IGF-1, so you need a lot of it and results vary. An analogue that evades them works at much lower concentrations, more consistently, and more cheaply. That is the problem IGF-1 LR3 was engineered to solve.
Every feature that makes it distinctive exists to solve a problem in a laboratory, not a problem in a person. That origin explains most of the confusion around it.
Why the reasoning is appealing
IGF-1 signalling genuinely does drive tissue growth. That is real biology, not marketing. So the chain of reasoning — IGF-1 grows tissue, this is a stronger longer-lasting IGF-1, therefore more growth — sounds solid.
What is missing is the last step. No published human trial evidence for this analogue was located. The claim rests entirely on the mechanism being plausible, which is not the same as it having been tested.
The reason a long-acting version is not a medicine
Binding proteins are not an inconvenience. They are regulation.
IGF-1 signalling drives cell proliferation broadly, not selectively in muscle. A version engineered specifically to evade the body's control system removes a brake that exists for a reason, and does so everywhere at once.
This concern is well recognised in the literature, and it is why long-acting IGF-1 analogues have not been developed into casual therapeutics. The property that makes IGF-1 LR3 useful in a dish is the same property that makes it a poor candidate for a person.
Where it stands
Approved as a medicine: nowhere — and it was never developed as one, so calling it an unapproved drug slightly overstates the case. It is a research reagent that ended up in a different catalogue.
Human evidence: none located.
Related entries in this library: follistatin is sold on the other muscle mechanism — blocking myostatin rather than driving IGF-1 signalling — and the only trial that administers it delivers a gene, not a protein. The muscle-growth pathway that has reached large human trials is receptor blockade with the antibody bimagrumab, now tested beside GLP-1 drugs.
Last checked
2026-09-07.